Takeda's Veyvondi approved for NHS England use

25 September 2020

Following a review meeting in July 2020, the NHS England Clinical Priorities Advisory Group (CPAG) has provided a positive recommendation for the routine commissioning of Veyvondi (vonicog alfa), the first and only recombinant von Willebrand factor (VWF) treatment for adults with von Willebrand disease (VWD), Japanese pharma major Takeda’s (TYO: 4502) UK subsidiary announced today.

Vonicog alfa was granted European Marketing Authorization in August 2018 and is indicated in adults (aged 18 and older) with VWD, when desmopressin treatment alone is ineffective or not indicated for the:

treatment of hemorrhage and surgical bleeding;
prevention of surgical bleeding
vonicog alfa should not be used in the treatment of hemophilia A.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK